NORWOOD, MA -- (Marketwired) -- 06/16/14 -- Corbus Pharmaceuticals Holdings, Inc., an emerging drug development company focused on the development and commercialization of its lead product candidate, Resunab, for the treatment of rare ("orphan") life-threatening inflammatory diseases, announced today that Yuval Cohen, Ph.D., Chief Executive Officer, will be presenting at the 2014 BIO International Convention on Thursday, June 26, 2014, at 9:30 a.m. Pacific Time in the Mission Beach Room at the San Diego Convention Center in San Diego, California.
Dr. Cohen will provide a business update and discuss the clinical development plans for Resunab, the Company's lead product candidate for the treatment of cystic fibrosis and diffuse scleroderma. Additionally, Dr. Cohen and Dr. Mark Tepper, Chief Scientific Officer at Corbus, will be available to participate in one-on-one meetings with convention attendees through the BIO One-on-One Partnering System.
About the BIO International Convention
The BIO International Convention will highlight the latest trends and the newest opportunities for executives, investors, scientists, policy leaders, and media from around the world. Speakers at the sessions will share breakthroughs in medicine, diagnostics, the environment, energy production, business operations, financing, partnerships, policy issues and food and agriculture. The Convention also features the BIO Business Forum, a unique platform for biotechnology and pharmaceutical companies, academic research institutions, and investors from around the world to gather and discuss strategic opportunities. For registration, conference agenda and exhibitor information, visit convention.bio.org.
Resunab is a novel synthetic oral drug with unique anti-inflammatory and anti-fibrotic activity. Pre-clinical and Phase 1 studies have shown Resunab to have a favorable safety profile coupled with promising potency in pre-clinical models. Resunab binds to the CB2 receptor of immune cells and triggers a process known as "inflammatory resolution," in effect turning chronic inflammation "off."
About Corbus Pharmaceuticals
Corbus Pharmaceuticals is a clinical stage biopharmaceutical company, focused on the development and commercialization of novel therapeutics to treat rare ("orphan"), life-threatening inflammatory-fibrotic diseases with clear unmet medical needs. Our lead product candidate Resunab is a novel oral anti-inflammatory drug scheduled to commence Phase 2a clinical trials for the treatment of cystic fibrosis and diffuse scleroderma in 2015. For more information, please visit www.CorbusPharma.com.
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the possibility of unfavorable results from studies and clinical trials involving Resunab or other product candidates. Corbus Pharmaceuticals Holdings, Inc. also faces risks related to its ability to enroll patients in studies and may need to modify or delay these studies. As a result, Resunab may never be successfully commercialized. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. All forward-looking statements are based on information currently available to Corbus Pharmaceuticals Holdings, Inc. and the Company assumes no obligation to update any such forward-looking statements.